Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | CENBF | Common Stock | 13.3K | Jul 12, 2017 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | CENBF | Convertible Note | Jul 12, 2017 | Common Stock | 62.5K | $1.60 | Direct | F2, F3 | ||||||
holding | CENBF | Convertible Note | Jul 12, 2017 | Common Stock | 125K | $1.60 | Direct | F2, F3 | ||||||
holding | CENBF | Convertible Note | Jul 12, 2017 | Common Stock | 156K | $1.60 | Direct | F2, F3 | ||||||
holding | CENBF | Convertible Note | Jul 12, 2017 | Common Stock | 313K | $1.60 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | Harold Aubrey de Lavenu (the "Reporting Person") was appointed to his position with CEN Biotech, Inc. (the "Issuer") on July 12, 2017 and owned 13,321 shares of the Issuer's common stock on such date. On April 2, 2021, the Issuer appointed the Reporting Person to serve as a Vice President of the Issuer effective as of April 2, 2021 |
F2 | Additionally the Reporting Person owned convertible notes on July 12, 2017, which the Reporting Person purchased from the Issuer which were at such time and still are convertible into 656,250 shares of the Issuer's common stock. |
F3 | The convertible notes included in this table matured on May 12, 2018, November 25, 2018, December 14, 2018, and February 19, 2019, respectively, (the "Maturity Dates"), however, the ability to convert the notes into shares did not expire on the Maturity Dates of the notes. |